Lashuel, H.A., Hartley, D.M., Balakhaneh, D., Aggarwal, A., Teichberg, S. and Callaway, D.J.E. (2002) New Class of Inhibitors of Amyloid-β Fibril Formation: Implications for the Mechanism of Pathogenesis in Alzheimer’s Disease. Journal of Biological Chemistry, 277, 42881-42890.
https://doi.org/10.1074/jbc.M206593200

has been cited by the following article:

• TITLE: Cannabidiol-Mediated Sequestration of Alzheimer’s Amyloid-β Peptides in ADDL Oligomers

  AUTHORS: Yang Li, Fengyuan Zhang, Caroline E. Herron, Ivonne Rosales, Alejandro Heredia, Nicolae-Viorel Buchete, Brian J. Rodriguez

  KEYWORDS: Cannabidiol, Amyloid, Alzheimer’s Amyloid-β Peptides, Aβ-Derived Diffusible Ligands, Atomic Force Microscopy, Amyloid Peptide Sequestration

  JOURNAL NAME: American Journal of Molecular Biology, Vol.13 No.2, March 3, 2023

  ABSTRACT: Cannabidiol (CBD), one of the most studied phytocannabinoids, is non-psychotropic and can induce protective effects on the central nervous system against acute and chronic brain injury. Interestingly, CBD inhibits processes relating to amyloid beta (Aβ)-induced neurotoxicity in mouse models of Alzheimer’s disease, though the detailed molecular mechanism underlying the CBD neurotoxicity modulation is not fully understood. In this study, using atomic force microscopy, we find that CBD promotes the aggregation of Aβ peptides, enhancing the formation of Aβ oligomers, also known as Aβ-derived diffusible ligands (ADDLs). The CBD-mediated sequestration of Aβ monomers in soluble ADDLs could reduce neurotoxicity. This study highlights a possible role of CBD in modulating the formation of ADDL aggregates and provides insight into potentially neuroprotective properties of CBD in Alzheimer’s disease.